Compare FIRY & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIRY | TNYA |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.9M | 153.2M |
| IPO Year | 2020 | 2021 |
| Metric | FIRY | TNYA |
|---|---|---|
| Price | $12.01 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | 145.5K | ★ 2.7M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,496,000.00 | N/A |
| Revenue This Year | $22.11 | N/A |
| Revenue Next Year | $7.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.52 | N/A |
| 52 Week Low | $7.92 | $0.52 |
| 52 Week High | $14.12 | $2.20 |
| Indicator | FIRY | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 57.19 | 41.56 |
| Support Level | $9.31 | $0.53 |
| Resistance Level | $14.02 | $0.82 |
| Average True Range (ATR) | 0.84 | 0.03 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 40.19 | 34.77 |
Firy Inc, formerly Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. Its reportable segments are: the Skillz segment and the RZR segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is a performance marketing platform that enables advertisers to acquire, retain, and monetize users across mobile, connected television (CTV), and other digital channels. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube, among others. It generates the majority of its revenue from the Skillz segment. Geographically, the company derives its key revenue from the United States.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.